 | |
 | |
| Company type | Public |
|---|---|
| NYSE: AGN S&P 500 Component | |
| Industry | Branded and generic pharmaceuticals, and pharmaceutical research and development. |
| Founded | Est 2015 through the acquisition of Allergan, incbyActavis, plc and the subsequent name change |
| Founder | Allen Chao, Ph.D. and David Hsia, Ph.D. |
| Headquarters | Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States. |
Number of locations | 40 manufacturing facilities, 27 global R&D centers and marketing/sales facilities worldwide. |
Area served | ~100 Countries |
Key people | Paul Bisaro, Executive Chairman, Brenton L. Saunders President and CEO |
| Products | Branded and generic pharmaceuticals |
| Revenue | US$ 4.2 billion(Q1 2015) [1] |
 US$ 1.090 billion (2014) | |
 -US$ 1.630 billion (2014) | |
| Total assets | US$ 6.881 billion (2014) |
| Total equity | US$ 28.335 billion (2014) |
Number of employees | 30,000 (June 2015) |
| Website | www |
On February 18, 2015, the entity formerly known as Actavis, plc announced its intention to change its name to Allergan, plc. This was completed as of June 15, 2015.[2][3]
After the acquisition of Allergan, inc by Actavis, plc, the new company made its first acquisition on July 6, when the company acquired start-up, Oculeve, for $125 million.[4] On July 7 the company announced it would acquire Merck & Cos late stage CGRP migraine portfolio, as well as two experimental drugs (MK-1602 and MK-8031) for $250 million.[5] In July, Allergan agreed to sell off its small molecule generic drug business, not including its biosimilars business, to Teva Pharmaceutical Industries for $40.5 billion ($33.75 billion in cash and $6.75 billion worth of shares).[6][7] A day later, the company announced it would acquire Naurex Inc for $560 million with more tied to regulatory milestones.[8][9] In September the company announced it would acquire opthalmic device start-up AqueSys for $300 million plus future sums tied to approval/sales milestones.[10]
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Allergan, plc
(formerly known as Actavis until June 2015 when it adopted Allergans name) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
